Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting.
Cuvillier
Olivier
O
CNRS, Institut de Pharmacologie et de Biologie Structurale, Toulouse, F-31000 France. cuvillio@me.com
Ader
Isabelle
I
Bouquerel
Pierre
P
Brizuela
Leyre
L
Malavaud
Bernard
B
Mazerolles
Catherine
C
Rischmann
Pascal
P
D017209:Apoptosis; D002518:Ceramides / Q000378:metabolism; D006801:Humans; D008246:Lysophospholipids / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction; D013107:Sphingolipids / Q000378:metabolism; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D000099157:Sphingosine Kinase
D002518:Ceramides; D008246:Lysophospholipids; D017853:Phosphotransferases (Alcohol Group Acceptor); D013107:Sphingolipids; D013110:Sphingosine; D000099157:Sphingosine Kinase; C060506:sphingosine 1-phosphate